Sparks commentary - Newron Pharmaceuticals

Healthcare

Sparks - Newron Pharmaceuticals

More on this equity
Newron Pharmaceuticals (SIX: NWRN) – EA Pharma confirms Phase III launch in Japan
Published by Arron Aatkar, PhD

Newron Pharmaceuticals has announced that its partner for Japan, EA Pharma (a subsidiary of Eisai), has initiated its Phase III clinical trial for evenamide. This is a key milestone for the clinical development of evenamide in schizophrenia as it represent an important requirement to satisfy regulators in the region. The announcement also reflects sustained progress for the candidate, which has a novel mechanism of action to address treatment-resistant schizophrenia.

Latest